Clinical Commissioning Policy Statement: Stereotactic ablative body radiotherapy for patients with locally advanced, inoperable, non-metastatic pancreatic carcinoma

Document first published:
Page updated:
Topic:
Publication type:

Stereotactic ablative body radiotherapy (SABR) is recommended to be available as a treatment option through routine commissioning for adults with locally advanced, inoperable, non- metastatic pancreatic carcinoma (LANPC) within the criteria set out in this document.